Option chain shows key data for Actinogen Medical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Actinogen Medical.

Actinogen Medical (OTC:ATGGF) Stock, Option Chain

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Actinogen Medical Ltd

Tandy Leather Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLF#NASDAQ">TLF</a>) reported quarterly earnings of $0.04 per share. This is a 82.61 percent decrease over earnings of $0.23 per share from the same period last year. The company reported $20.50 million in sales this quarter. This is a 1.66 percent decrease over sales of $20.84 million the same period last year.

Earnings

News

Tandy Leather Factory Q4 EPS $0.04 Down From $0.23 YoY, Sales $20.50M Down From $20.84M YoY

Energy Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>) sees FY2025 sales of $152.000 million-$164.000 million vs $159.14 million analyst estimate.

Guidance

ERII

Energy Recovery Sees FY2025 Sales $152.000M-$164.000M vs $159.14M Est

Insurance company Root Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) reported fourth-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a>
Here are the key highlights.
 What Happened: Root reported fourth-quarter revenue of $326.7 million, beating a Street consensus estimate of $291.0 million according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022625&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company <a href="https://ir.joinroot.com/news-releases/news-release-details/root-inc-announces-2024-fourth-quarter-and-full-year-results">reported </a>fourth-quarter earnings per share of $1.62, beating a Street consensus estimate of a loss of 44 cents per share.
The company reported policies in force grew 21% year-over-year in the quarter. Gross premiums written were up 18% year-over-year in the quarter.
Gross accident period losses were down in the quarter.
Root reported positive net income for the second consecutive quarter and had a positive net income of $31 million for the full fiscal year, an improvement of $178 million from the previous fiscal year.
The company called 2024 "a landmark year" and said it was made possible by hard decisions made in 2022 and 2023.
"Ten years ago, we believed that modern quantitative methods would allow us to grow at better loss ratios than the industry. Today our loss ratio is among the best in the industry," the company said.
Root said it continues to invest in infrastructure and growth, which should translate to "strong calendar period results" as the company gains scale.
"We believe our patience and foundation in data science will continue to bear fruit that will ultimately accrue to long-term stakeholders."
ROOT Price Action: Root stock is up 17.52% to $116 in after-hours trading Wednesday versus a 52-week trading range of $20.22 to $141.23.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/quote/ROOT/analyst-ratings">Analyst Ratings For ROOT </a></li>
</ul>
Photo: MacroEcon via Shutterstock

After-Hours Center

Movers

Trading Ideas

Insurance

ROOT

Why Shares Of Insurance Company Root Are Soaring Wednesday

MESO

Mesoblast H1 2025 EPADS $(4.20) Down From $(3.72) YoY; Revenue $3.156M Down From $3.388M YoY

Cantor Fitzgerald analyst Charles Duncan downgrades Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Overweight to Neutral and raises the price target from $140 to $150.

Downgrades

Price Target

Analyst Ratings

JAZZ

Cantor Fitzgerald Downgrades Jazz Pharmaceuticals to Neutral, Raises Price Target to $150

Plymouth Industrial REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) is looking for FY2025 FFO of $1.85-$1.89 vs $1.97 analyst estimate..

PLYM

Plymouth Industrial REIT Sees FY2025 FFO $1.85-$1.89 vs $1.97 Est

Plymouth Industrial REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.46 by 13.04 percent. This is a 16.67 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $47.29 million which missed the analyst consensus estimate of $50.88 million by 7.05 percent. This is a 6.82 percent decrease over sales of $50.75 million the same period last year.

Earnings Misses

Plymouth Industrial REIT Q4 FFO $0.40 Misses $0.46 Estimate, Sales $47.29M Miss $50.88M Estimate

Joby Aviation Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) reported its fourth-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43989539/joby-reports-record-certification-progress-and-delivery-of-second-aircraft-to-us-air-force-at-edwa">details from the report. </a>
The Details: Joby Aviation reported quarterly losses of 34 cents per share, which missed the analyst consensus estimate for a loss of 20 cents. Quarterly revenue came in at $55,000, which beat the analyst consensus estimate of $45,800 and is a decrease from revenue of $1.03 million in the prior year&#8217;s quarter.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43949800/tesla-competes-against-chinese-rivals-with-one-hand-tied-behind-its-back-analyst"> Tesla Competes Against Chinese Rivals &#8216;With One Hand Tied Behind Its Back&#8217;: Analyst</a>
Joby ended the fourth quarter with $933 million in cash, cash equivalents and investments in marketable securities, not including expected Toyota investments totaling $500 million, to be made in two equal tranches of $250 million.
&#8220;The sector-leading progress we made throughout 2024 puts Joby in a great position to capitalize on the opportunities presented by America&#8217;s renewed focus on innovation and manufacturing,&#8221; JoeBen Bevirt, founder and CEO, said. 
&#8220;As well as delivering record progress on certification, we scaled our manufacturing, delivered two aircraft to the Department of Defense and flew 561 miles with a hybrid, hydrogen-electric variant of our aircraft, bringing the flight test fleet to a total of five aircraft,&#8221; Bevirt added. 
JOBY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Joby Aviation shares are up 3.33% after hours at $6.93 Wednesday.  
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains &#8216;Largely Stuck&#8217;&nbsp;</a></li>
</ul>
Photo: Courtesy of Joby Aviation, Inc.

Tech

JOBY

Joby Aviation Stock Climbs After Q4 Results: Here's Why

Cactus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.70 by 1.43 percent. This is a 12.35 percent decrease over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $272.12 million which missed the analyst consensus estimate of $277.15 million by 1.82 percent. This is a 1.00 percent decrease over sales of $274.87 million the same period last year.

Earnings Beats

Cactus Q4 Adj $0.71 Beats $0.70 Estimate, Sales $272.12M Miss $277.15M Estimate

Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has outperformed the market over the past 5 years by 51.28% on an annualized basis producing an average annual return of 65.92%. Currently, Modine Manufacturing has a market capitalization of $4.57 billion. 
Buying $100 In MOD: If an investor had bought $100 of MOD stock 5 years ago, it would be worth $1,203.46 today based on a price of $87.01 for MOD at the time of writing.
<h3>Modine Manufacturing's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740609044_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Titan Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWI#NYSE">TWI</a>) sees Q1 sales of $450.000 million-$500.000 million vs $466.08 million analyst estimate.

Titan Intl Sees Q1 Sales $450.000M-$500.000M vs $466.08M Est

A Minnesota couple's dream vacation turned into a nightmare when a routine illness led to a massive medical bill. Mike Cameron, a truck driver from Braham, and his girlfriend, Tami Masterman, were excited for their weeklong cruise on Norwegian Encore, a trip they had won. It was meant to be a special getaway, especially for Tami, who had recently undergone surgery for lung cancer.
<h2 class="wp-block-heading">A Shocking Medical Bill for Flu Treatment</h2>
However, just days into the trip, Mike fell ill with the flu. His oxygen levels dropped, and he was admitted to the ship's medical ICU. Over the next 63 hours, he received oxygen, IV medications, and other treatments, though he repeatedly asked to be discharged. The couple <a href="https://www.youtube.com/watch?v=HNCZCqIEmCc">told</a> FOX 9 Minneapolis-St. Paul, they believed they were covered, as Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) staff assured them their <a href="https://www.benzinga.com/money/best-travel-insurance">travel insurance</a> would take care of up to $20,000 in medical costs.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
That relief quickly vanished when they were handed a $47,638 bill on the final day of the cruise. To make matters worse, Norwegian Cruise Line immediately maxed out both of their credit cards, charging them $26,000 without prior warning. Now, the couple is scrambling to deal with the financial fallout.
<h2 class="wp-block-heading">Insurance Nightmare</h2>
Mike and Tami, like many tourists, bought travel insurance in the hopes that it would shield them in the event of an emergency. However, after returning home, they found themselves stuck in a bureaucratic loop. Until their own health insurance processed the claim, their travel insurance company would not pay for the expenses. But their health insurer declined, stating the treatment was received abroad and not within their network. Meanwhile, <a href="https://www.benzinga.com/news/24/04/38299693/heres-the-gravest-error-you-can-make-with-credit-cards-like-owing-money-to-loan-sharks">interest on the unpaid balance</a> continues to pile up.
Trending: Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares"> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</a>
"We didn't even get a chance to pay," Tami told FOX 9. "They just took it out. Maxed our two credit cards out. You start thinking you're going to lose your house, you're going to lose your cars."
<h2 class="wp-block-heading">Public Outrage and a Growing Fundraiser</h2>
After their story aired, frustration over cruise ship medical costs exploded online. Many were stunned that a flu diagnosis could result in such an astronomical bill, especially when the couple had taken steps to ensure they were covered.
Mike's daughter, Krystal Cameron, launched a <a href="https://www.gofundme.com/f/relieve-mike-and-tamis-medical-burden">GoFundMe</a> campaign to help ease the burden. So far, the fundraiser has collected over $4,765 toward its $10,000 goal.&nbsp;
See Also: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
<h2 class="wp-block-heading">Norwegian Defends Its Prices</h2>
Norwegian Cruise Line told them in a letter that the bill was &#8220;accurate&#8221; and that its pricing is "competitive," FOX 9 reported. Norwegian told FOX-9 that it was looking into the matter.&nbsp;
<h2 class="wp-block-heading">A Warning for Future Travelers</h2>
This case serves as a stark warning for anyone planning a cruise. While onboard medical care is often necessary, it comes at a steep price—and even travel insurance may not offer the safety net travelers expect.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

NCLH

A $47,000 Flu? Minnesota Truck Driver Stunned By Massive Cruise Ship Medical Bill Despite Having Travel Insurance

Titan Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWI#NYSE">TWI</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.13) by 169.23 percent. This is a 73.53 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $383.57 million which missed the analyst consensus estimate of $394.38 million by 2.74 percent. This is a 1.70 percent decrease over sales of $390.20 million the same period last year.

Titan Intl Q4 Adj $0.09 Beats $(0.13) Estimate, Sales $383.57M Miss $394.38M Estimate

NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.66 by 4.55 percent. This is a 30.19 percent increase over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $75.37 million which beat the analyst consensus estimate of $68.87 million by 9.43 percent. This is a 31.00 percent increase over sales of $57.53 million the same period last year.

NEWT

NewtekOne Q4 EPS $0.69 Beats $0.66 Estimate, Sales $75.37M Beat $68.87M Estimate

Seacor Marine Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMHI#NYSE">SMHI</a>) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.67) by 40.3 percent. This is a 570 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $69.81 million which beat the analyst consensus estimate of $65.58 million by 6.44 percent. This is a 4.48 percent decrease over sales of $73.08 million the same period last year.

SMHI

Seacor Marine Hldgs Q4 EPS $(0.94) Misses $(0.67) Estimate, Sales $69.81M Beat $65.58M Estimate

IonQ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) reported its fourth-quarter results after Wednesday's closing bell. Here's a look at the details from the report and additional <a href="https://www.benzinga.com/pressreleases/25/02/b43989544/ionq-announces-fourth-quarter-and-full-year-2024-financial-results">announcements from the company. </a>
The Details:&nbsp;IonQ reported quarterly losses of&nbsp;93 cents&nbsp;per share, which missed the analyst consensus estimate of&nbsp;a loss of 21 cents. Quarterly revenue came in at&nbsp;$11.71 million,&nbsp;which beat the analyst consensus estimate of&nbsp;$9.93 million&nbsp;and is an increase over revenue of&nbsp;$6.11 million&nbsp;from the same period last year.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43949800/tesla-competes-against-chinese-rivals-with-one-hand-tied-behind-its-back-analyst"> Tesla Competes Against Chinese Rivals &#8216;With One Hand Tied Behind Its Back&#8217;: Analyst</a>
&#8220;We had IonQ&#8217;s best year yet in 2024, exceeding the high ends of both our bookings and revenue guidance ranges and making truly significant technical strides,&#8221; said Peter Chapman, IonQ&#8217;s executive chair.
&#8220;As we enter 2025, IonQ has a strong pipeline that we believe will enable us to lead in the era of commercial advantage. Last year, our rapidly expanding quantum networking business line closed three major networking contracts. McKinsey expects the quantum networking industry to be worth $10-$15 billion per year within the next decade,&#8221; noted Chapman.
IonQ announced an at-the-market equity offering under which it may offer and sell shares of its common stock having an aggregate offering price of up to&nbsp;$500 million. 
Additionally, the company <a href="https://www.benzinga.com/pressreleases/25/02/b43989542/ionq-to-acquire-geneva-based-id-quantique-enters-into-global-quantum-strategic-partnership-with-sk">announced</a> two definitive agreements with SK Telecom and ID Quantique. One is to acquire a controlling stake in ID Quantique, and the other is to enter into a strategic partnership focused on quantum with SK Telecom. The transactions will be paid in IonQ common stock.
IonQ <a href="https://www.benzinga.com/pressreleases/25/02/b43989464/ionq-names-niccolo-de-masi-as-president-chief-executive-officer">also announced</a> that the company&#8217;s board of directors appointed Niccolo de Masi as president and CEO, effective immediately, and Peter Chapman will continue in the leadership role of IonQ&#8217;s executive chair.
IONQ Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, IonQ shares are down 10.93% after hours at $26.66 Wednesday.&nbsp;&nbsp;
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains &#8216;Largely Stuck&#8217;&nbsp;</a></li>
</ul>
Image courtesy of IonQ, Inc.

Management

IONQ

IonQ Q4 EPS Miss, $500 Million Offering, CEO Appointment, Acquires Stake In ID Quantique: Details

AlTi Global, Inc. ("AlTi") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>), today announced the appointment of Mike Harrington to Chief Financial Officer, effective immediately. Mr. Harrington replaces Stephen Yarad and brings nearly four decades of experience in financial services across the banking, investment management and asset management industries to the position.

ALTI

AlTi Global Appoints Mike Harrington Chief Financial Officer, Effective Immediately

Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) FY2026 Revenue expected to be more than 975M

Stoneridge FY2026  Revenue expected to be more than 975M

Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) sees FY2025 sales of $860.000 million-$890.000 million vs $948.78 million analyst estimate.

Stoneridge Sees FY2025 Sales $860.000M-$890.000M vs $948.78M Est

Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.04) by 350 percent. This is a 250 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $218.20 million which missed the analyst consensus estimate of $222.04 million by 1.73 percent. This is a 4.92 percent decrease over sales of $229.50 million the same period last year.

Comments

Actinogen Medical

Actinogen Medical (ATGGF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga